Mesothelioma v/s adenocarcinoma of lung do serum markers help?

Our plain-English summary of Mesothelioma v/s adenocarcinoma of lung do serum markers help?, by N. Gupta (Lung India, 2008).

The study

• Author: N. Gupta
• Journal: Lung India
• Published: 2008;25(4):172
• Read it: PubMed · Publisher · Free full text

In plain English

This was a one-page letter to the editor, not an original study, and it reported no new patients or data. The author was responding to a case report by Ahuja and colleagues about a 25-year-old man with pleural thickening. The letter discussed whether blood (serum) markers could help tell malignant mesothelioma apart from adenocarcinoma of the lung. It noted that mesothelioma is usually diagnosed by histology and immunohistochemical stains, with electron microscopy deciding unusual cases. It focused on a marker called soluble mesothelin related protein (SMR). Citing earlier work by others, the letter said a raised SMR level was reported to indicate mesothelioma with a sensitivity of 84% and a specificity of 100%. It added that ovarian, lung and breast carcinomas can also raise SMR. It said none of seven lung adenocarcinoma patients in a study by Robinson and colleagues had raised SMR, and that SMR levels were related to tumor size. It also said higher SMR in asbestos-exposed people might predict disease or mark early disease in some patients. The author concluded that SMR testing may prove a step toward better diagnosis of mesothelioma, and probably toward distinguishing it from lung adenocarcinoma.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Letter to the editor commenting on a published case report; no original data
• Who was studied: No study population. The letter responds to a case report of a 25-year-old male with pleural thickening by Ahuja et al.
• Exposure: No exposure was studied. The letter mentions asbestos-exposed individuals only when discussing SMR as a possible early marker, citing other work.
• Main results:
  • No results of its own. Citing other authors, the letter states that a raised serum SMR concentration was reported to indicate mesothelioma with a sensitivity of 84% (and a specificity of 100%).
  • The letter states that ovarian, lung and breast carcinomas can also raise SMR concentrations, so specificity falls below 100% in studies including such patients, as in the study by Scholler and colleagues.
  • The letter reports that in the study by Robinson et al., none of seven patients with lung adenocarcinoma had raised SMR concentrations.
  • The letter states that SMR levels are related to tumor load, with significantly higher levels when maximum pleural tumor width was more than 3 cm.
• The authors' conclusion: The author concluded that SMR testing is probably the first commercially available blood test of this kind and may prove a step toward better diagnosis of mesothelioma, and probably toward differentiating it from lung adenocarcinoma.

Topics

Medical terms in this study, explained in our Lexicon: Mesothelioma, Adenocarcinoma.

Related studies

• Serum hyaluronan as a disease marker — T.C. Laurent, U.B. Laurent, et al. (1996)
• Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma — J. Creaney, D. Yeoman, et al. (2008)
• Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial — B. Trabert, L. Pinto, et al. (2014)
• Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma — C. Tabata, E. Shibata, et al. (2013)
• Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma — K. Shiomi, Y. Hagiwara, et al. (2008)
• Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers — M. Maeda, O. Hino (2006)

Browse more research in Lung India, or return to medical research.